Annals of Oncology最新文献

{"title":"80P Sequencing matters: Real-world outcomes of second-line anti-EGFR versus anti-VEGF therapy in metastatic colorectal cancer","authors":"D. Martin Sanchez, P. Delgado Garces, A. Acosta, M.D.R. Morales Herrero, J.R. Rodriguez Monwbray, A. Lopez-Ladrón García, M.J. Valladares Ayerbes, M.L. Limon, I. Gallego Jimenez","doi":"10.1016/j.annonc.2026.05.081","DOIUrl":"10.1016/j.annonc.2026.05.081","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S30"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148523887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Notice and disclaimer","authors":"","doi":"10.1016/S0923-7534(26)00921-X","DOIUrl":"10.1016/S0923-7534(26)00921-X","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page iii"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148529609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"61P Neoadjuvant ipilimumab, nivolumab, and high-dose vitamin C in pMMR/MSS colon cancer: Results of the ALFEO pilot study","authors":"A. Amatu, F.M. Tosi, T. Troiani, F. Di Nicolantonio, A. Carignano, S. Ghezzi, K.B. Bencardino, E.F. Bonazzina, V. De Falco, D. Piscazzi, F. Villa, E. Forti, P. Carnevali, F. Maione, G. Ferrari, F. Ciardiello, A. Bardelli, S. Abrignani, S. Siena, A. Sartore Bianchi","doi":"10.1016/j.annonc.2026.05.063","DOIUrl":"10.1016/j.annonc.2026.05.063","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S24"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"78P Prognostic impact of BRAFV600E mutation in MSI-H/dMMR metastatic colorectal cancer: A large real-world propensity-matched analysis","authors":"F.G. Sullo, L. Esposito, B. Ceredi, G. Marisi, F. Rebuzzi, F. Rusconi, S. Williford, P. Ulivi, A. Passardi","doi":"10.1016/j.annonc.2026.05.079","DOIUrl":"10.1016/j.annonc.2026.05.079","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S29"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"56P Time-dependent recurrence hazards after curative resection in stage II/III colorectal cancer: Integrated analysis of Japanese randomized controlled trials (JCOG2310A-S4)","authors":"Y. Otsuka, K. Tashiro, H. Osumi, K. Kataoka, Y. Shimada, M. Inomata, T. Hamaguchi, Y. Takii, J. Mizusawa, Y. Sano, T. Suto, K. Murata, T. Adachi, H. Ueno, S. Ikeda, K. Komori, M. Shiozawa, S. Tsukamoto, A. Takashima, Y. Kanemitsu","doi":"10.1016/j.annonc.2026.05.058","DOIUrl":"10.1016/j.annonc.2026.05.058","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S22"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531965","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"57P VIVA trial: Randomized comparison of adjuvant regorafenib plus durvalumab versus observation in stage IV colorectal cancer with no evidence of disease","authors":"A. Pastorino, S. Lonardi, C. Cremolini, J. Giuliani, G. Rosati, O. Brunetti, F. Zustovich, F. Daniel, L. Pala, K. Cerma, A. Pessino, V. Andretta, A. Fabbrocini, R. Esposto, M.P. Di Palma, I. De Simone, A. Sobrero","doi":"10.1016/j.annonc.2026.05.059","DOIUrl":"10.1016/j.annonc.2026.05.059","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S23"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148531966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"54P Shared hereditary pathways in colorectal and endometrial cancers: A Lynch syndrome-focused systematic review and meta-analysis","authors":"L. Basmpana, C. Margioula-Siarkou, S. Petousis","doi":"10.1016/j.annonc.2026.05.056","DOIUrl":"10.1016/j.annonc.2026.05.056","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Pages S21-S22"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148532013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma","authors":"J.C. Hassel ,&nbsp;A. Arance ,&nbsp;M.S. Carlino ,&nbsp;L. Mortier ,&nbsp;P.A. Ascierto ,&nbsp;P. Rutkowski ,&nbsp;S. Sandhu ,&nbsp;C. Coetzee ,&nbsp;I. Puzanov ,&nbsp;S.B. Karaca ,&nbsp;A.M. Eggermont ,&nbsp;O. Hamid ,&nbsp;S. Grabbe ,&nbsp;A. Poklepovic ,&nbsp;T. Amaral ,&nbsp;D. Schadendorf ,&nbsp;B. Schilling ,&nbsp;A. Vedel Christiansen ,&nbsp;B. Wang ,&nbsp;A. Wakatsuki Pedersen ,&nbsp;I.M. Svane","doi":"10.1016/j.annonc.2026.04.010","DOIUrl":"10.1016/j.annonc.2026.04.010","url":null,"abstract":"<div><h3>Background</h3><div>IO102-IO103, an investigational, immune-modulatory cancer vaccine, targets both tumor cells and immune-suppressive cells within the tumor microenvironment through activation and expansion of T cells against indoleamine 2,3-dioxygenase 1–positive and/or programmed death ligand 1 (PD-L1)-positive cells.</div></div><div><h3>Patients and methods</h3><div>This open-label, phase III trial randomly assigned 407 patients with untreated advanced melanoma in a 1:1 ratio to receive subcutaneous IO102-IO103 (85 μg each) plus pembrolizumab 200 mg intravenously every 3 weeks or pembrolizumab alone for up to 2 years. The primary endpoint was progression-free survival (PFS) by blinded independent central review per RECIST v1.1.</div></div><div><h3>Results</h3><div>The median PFS was 19.4 months [95% confidence interval (CI) 9.7 to not reached] for IO102-IO103 plus pembrolizumab versus 11.0 months (95% CI 6.0-14.8) for pembrolizumab [hazard ratio (HR) (95% CI) 0.77 (0.58-1.00), <em>P</em> = 0.0558]; the statistical significance threshold (<em>P</em> ≤ 0.045) was missed. A longer PFS was observed in the combination arm across most subgroups, notably in patients with PD-L1-negative tumors [median PFS 16.6 versus 3.0 months (HR 0.54, 95% CI 0.35-0.85)], anti-PD-1 naïve patients [24.8 versus 11.0 months (HR 0.74, 95% CI 0.56-0.98)], proto-oncogene <em>B-Raf</em> (BRAF)-mutated tumors, or elevated lactate dehydrogenase. There was no increase in the frequency of treatment-related adverse events grade ≥3 (14.5% versus 15.6%) or of serious adverse events (32.0% versus 32.3%) in the vaccine arm. Local vaccine-related injection site reactions were reported in 56.0% of patients and were mostly grade 1/2.</div></div><div><h3>Conclusions</h3><div>IO102-IO103 plus pembrolizumab prolonged PFS compared with pembrolizumab alone in patients with advanced melanoma in the first-line setting; however, statistical significance was missed for the primary endpoint. The combination was well tolerated with no added significant systemic toxicity. These data show the potential benefit of this combination in untreated advanced melanoma.</div></div>","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 7","pages":"Pages 999-1010"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"12P Clinical and molecular characteristics of patients with young onset colorectal cancer (YOCRC) in the Greek and Cypriot population: A-retrospective study","authors":"C. Cortas,&nbsp;Z. Saridaki-Zoras,&nbsp;D. Papamichael,&nbsp;M. Chondrozoumaki,&nbsp;G. Fountzilas,&nbsp;G. Pentheroudakis,&nbsp;E. Samantas,&nbsp;H. Kalofonos,&nbsp;C. Christodoulou,&nbsp;P. Papakostas,&nbsp;D.G. Pectasides,&nbsp;F. Zagouri,&nbsp;D. Bafaloukos,&nbsp;C. Matthaiou,&nbsp;G. Tsironis,&nbsp;I. Sougklakos","doi":"10.1016/j.annonc.2026.05.016","DOIUrl":"10.1016/j.annonc.2026.05.016","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S9"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148523788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"13P Clinical and molecular profile of PIK3CA-mutated advanced colorectal cancer: Insights from a Mexican cohort","authors":"M.D.C. Diaz Romero,&nbsp;D.A.D. Rubio,&nbsp;G. Paredes,&nbsp;S.M. Miyagui Adame,&nbsp;G. Calderillo Ruiz,&nbsp;M. Herrera Martinez,&nbsp;E.B. Ruiz-García,&nbsp;L.G. Lagarde Nube,&nbsp;J.A. Rubio Cordero,&nbsp;D. Sandoval,&nbsp;E.E. Santana Aguilar","doi":"10.1016/j.annonc.2026.05.017","DOIUrl":"10.1016/j.annonc.2026.05.017","url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"37 ","pages":"Page S9"},"PeriodicalIF":80.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148523789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}